Eli Lilly and Company (NYSE:LLY) Given New $1,605.00 Price Target at Scotiabank

Posted by Brian Himes on Oct 30th, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report) had its price target raised by equities research analysts at Scotiabank from $1,300.00 to $1,605.00 in a report issued on Friday, Benzinga reports. The firm presently has a “sector outperform” rating on the stock. Scotiabank‘s price objective would suggest a potential upside of 13.07% from the stock’s current price.

Several other brokerages also recently weighed in on LLY. TD Cowen reaffirmed a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Berenberg Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target for the company in a research report on Tuesday, September 15th. Royal Bank Of Canada upped their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a research report on Friday. Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Argus lifted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,391.29.

Check Out Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Stock Performance

NYSE LLY traded up $45.72 during trading hours on Friday, reaching $1,419.42. The stock had a trading volume of 3,114,127 shares, compared to its average volume of 2,933,308. Eli Lilly and Company has a 52-week low of $834.19 and a 52-week high of $1,449.68. The stock has a fifty day moving average of $1,194.34 and a 200 day moving average of $1,090.89. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a market cap of $1.34 trillion, a P/E ratio of 47.57, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.68 by $1.80. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period last year, the firm posted $7.02 EPS. Eli Lilly and Company’s revenue for the quarter was up 38.6% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 33.22 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

A number of large investors have recently modified their holdings of the stock. MFG Investments LLC purchased a new position in Eli Lilly and Company in the third quarter valued at approximately $773,000. Third View Private Wealth LLC raised its holdings in Eli Lilly and Company by 5.7% during the third quarter. Third View Private Wealth LLC now owns 2,049 shares of the company’s stock worth $2,371,000 after purchasing an additional 111 shares in the last quarter. Provenance Wealth Advisors LLC lifted its position in Eli Lilly and Company by 5,300.0% in the third quarter. Provenance Wealth Advisors LLC now owns 1,350 shares of the company’s stock valued at $1,562,000 after acquiring an additional 1,325 shares during the last quarter. Ackerman Capital Advisors LLC grew its stake in Eli Lilly and Company by 19.7% during the 3rd quarter. Ackerman Capital Advisors LLC now owns 322 shares of the company’s stock worth $373,000 after buying an additional 53 shares during the last quarter. Finally, One Day In July LLC boosted its stake in Eli Lilly and Company by 1.6% during the 3rd quarter. One Day In July LLC now owns 567 shares of the company’s stock worth $656,000 after purchasing an additional 9 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Strong Q3 results: Lilly reported revenue of $24.4 billion, up approximately 39% year over year, while adjusted EPS of $7.48 substantially exceeded analyst expectations. Lilly Q3 2026 results
Positive Sentiment: GLP-1 sales remained the primary catalyst: Mounjaro revenue rose 65% to $10.7 billion and Zepbound generated $5.35 billion, reinforcing Lilly’s leadership in diabetes and obesity treatments. Combined sales exceeded $16 billion. Tirzepatide Q3 sales
Positive Sentiment: Higher outlook: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion. Expanding Medicare access, middle-income demand and continued obesity-drug adoption supported the improved outlook. Lilly earnings call highlights
Positive Sentiment: Pipeline momentum improved: Positive Phase 3 results for experimental obesity and diabetes drug retatrutide versus Ozempic strengthened expectations for Lilly’s next generation of metabolic medicines. The FDA also approved additional Mounjaro cardiovascular-risk labeling and once-weekly basal insulin Onswik. Retatrutide trial results
Positive Sentiment: Analyst support: Royal Bank of Canada raised its price target from $1,500 to $1,600 and maintained an “outperform” rating, signaling confidence that earnings momentum can continue.
Neutral Sentiment: Lilly’s quarter included roughly $900 million of benefits from Jardiance milestones and favorable rebate and discount adjustments, factors that may not recur.
Negative Sentiment: Pricing and cost risks remain: Realized prices declined about 15%, with volume growth doing the work of offsetting lower prices. Lilly also recorded approximately $4.2 billion in acquired in-process research-and-development charges, while management acknowledged ongoing pricing pressure. Reuters Lilly outlook report

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.